Trial Profile
Phase II study of UCN-01 in relapsed or refractory systemic anaplastic large cell and mature T-cell lymphomas.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs UCN 01 (Primary)
- Indications Extranodal NK-T-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- 01 May 2017 Status changed from completed to discontinued as IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND.
- 01 May 2017 Status changed from completed to discontinued as IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND.
- 03 Oct 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.